
ARS Pharmaceuticals, Inc.: updates and filings
Price
$3.69
November 18, 2026Market cap $366M
What Ploutos Investor adds for ARS Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 39% since Nov 5, 2026, when the 10-Q these figures come from was filed ($2.65 then, $3.69 on Nov 18, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jul 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 17, 2026Officer or director changeForm8-K
- Jul 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 7, 2026Officer or director changeForm8-K
- Jun 25, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 15, 2026Results of operations, Regulation FD disclosureForm8-K
- May 13, 2026Officer or director changeForm8-K
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Apr 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 24, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 9, 2026Shares registered for employeesFormS-8
- Mar 9, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 9, 2026Results of operations, Regulation FD disclosureForm8-K
- Feb 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jan 21, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 12, 2025Filing (amendment)Form144/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jul 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 17, 2026 | 8-K | Officer or director change | Document |
| Jul 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 7, 2026 | 8-K | Officer or director change | Document |
| Jun 25, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 15, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| May 13, 2026 | 8-K | Officer or director change | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 24, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 9, 2026 | S-8 | Shares registered for employees | Document |
| Mar 9, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 9, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Feb 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jan 21, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 12, 2025 | 144/A | Filing (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 12, 2016.
The full analysis
What do ARS Pharmaceuticals's filings show?
The filings are where every one of ARS Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.